Loading clinical trials...
Loading clinical trials...
Evaluation of Persistence of Immunogenicity Following an Open-labelled, Randomized Controlled Trial Evaluating Non-inferiority of 1+1 Compared to 2+1 Dosing Schedules of 10-valent and 13-valent Pneumococcal Conjugate Vaccine in South Africa
Conditions
Interventions
PCV10
PCV13
Locations
1
South Africa
Chris Hani Baragwanath Academic Hospital - DST/NRF VPD RMPRU
Soweto, Gauteng, South Africa
Start Date
February 14, 2020
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
August 23, 2024
NCT06743529
NCT07409727
NCT06966284
NCT06494072
NCT07186933
NCT06169514
Lead Sponsor
University of Witwatersrand, South Africa
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions